Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844570 | 0.89 | ANPEP (0.53) | DPP8DPP7DPP4DPP9CPB1 | |
| SCHEMBL2840917 | 0.87 | KLK5 (0.59) | DPP8DPP7DPP4DPP9CASP3 | |
| Hydrochloric Acid SCHEMBL2843945 | 0.84 | ANPEP (0.47) | DPP8DPP7DPP4DPP9CPB1 | |
| SCHEMBL2845860 | 0.81 | KLKB1 (0.42) | DPP8DPP7DPP4DPP9CASP3 | |
| SCHEMBL3622112 | 0.78 | PSMB5 (0.46) | CPB1CASP3 | |
| Hydrochloric Acid SCHEMBL2849314 | 0.77 | PSMB5 (0.45) | CPB1CASP3 | |
| SCHEMBL14161287 | 0.76 | CPB1 (0.78) | CPB1CASP3CTSBCTSSCTSK | |
| SCHEMBL13712268 | 0.76 | CPB1 (0.78) | CPB1CASP3CTSBCTSSCTSK | |
| SCHEMBL10706890 | 0.75 | DPP8 (0.54) | DPP8DPP7DPP4DPP9ANPEP | |
| SCHEMBL2841932 | 0.75 | KLK7 (0.45) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | DPP8 1091/4885DPP7 1239/4885DPP4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.